StreetInsider.com News Articles

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Shah Rajeev M.

Wed, 10 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260610/26630531.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Shah Rajeev M.

Wed, 10 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260610/26630531.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Haviland Kate

Wed, 10 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260610/26630423.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Haviland Kate

Wed, 10 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260610/26630423.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Bowden Christopher

Wed, 10 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260610/26630430.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Bowden Christopher

Wed, 10 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260610/26630430.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Robertson Scott M.

Wed, 10 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260610/26630403.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Robertson Scott M.

Wed, 10 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260610/26630403.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Mazumdar-Shaw Kiran

Wed, 10 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260610/26630410.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Mazumdar-Shaw Kiran

Wed, 10 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260610/26630410.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: POWELL MICHAEL

Wed, 10 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260610/26630397.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: POWELL MICHAEL

Wed, 10 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260610/26630397.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Simson Jake

Wed, 10 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260610/26630385.html

Form 4 Bicara Therapeutics Inc. For: Jun 09 Filed by: Simson Jake

Wed, 10 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260610/26630385.html

Form 8-K Bicara Therapeutics Inc. For: Jun 09

Wed, 10 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260610/26629851.html

Form 8-K Bicara Therapeutics Inc. For: Jun 09

Wed, 10 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260610/26629851.html

Bicara Therapeutics (BCAX) Reiterated at Overweight by Cantor Fitzgerald

Tue, 02 Jun 2026 07:21:05 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight ratingon Bicara Therapeutics Inc (NASDAQ: BCAX).

The analyst commented, "Multiple good options coming to patients with head & neck cancers. Our consultant specializes in treating SCCHN and indicated that all three bispecifics in Phase 3 development (BCAX’s ficerafusp, GMAB’s [NC] petosemtamab, and JNJ’s amivantamab) are likely to be approved and adopted. In his view, there is value in simply recreating cetuximab’s wellestablished anti-EGFR benefits in a dossier eligible for approval, but he thinks all three drugs go above and beyond that in terms of their efficacy. He does not believe any of the

Form 144 Bicara Therapeutics Inc. Filed by: Meisner Lara

Mon, 01 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260601/26583428.html

Form 144 Bicara Therapeutics Inc. Filed by: Meisner Lara

Mon, 01 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260601/26583428.html

Bicara Therapeutics (BCAX) Reiterated at Overweight by Cantor Fitzgerald

Wed, 27 May 2026 07:29:08 -0400

Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Bicara Therapeutics Inc (NASDAQ: BCAX).

The analyst commented, "We hosted the Bicara senior management team (CEO, President, CMO, CCO, and VP of IR) for an investor lunch in New York today. Our meeting was hot on the heels of the latest clinical update on ficerafusp (EGFR x TGF-β BsAb) in patients with 1L HPV-negative HNSCC. BCAX shares are up 34% YTD (vs. +10% for the XBI), outperformance that we believe reflects investor appreciation for consistency of data generated by ficerafusp and greater optimism for its competitive positioning relative to GMAB’s (NC)

Form 4 Bicara Therapeutics Inc. For: May 21 Filed by: Hyep Ivan

Tue, 26 May 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260526/26551520.html

Form 4 Bicara Therapeutics Inc. For: May 21 Filed by: Hyep Ivan

Tue, 26 May 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20260526/26551520.html

Form 144 Bicara Therapeutics Inc. Filed by: Raben David

Tue, 26 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260526/26549732.html

Form 144 Bicara Therapeutics Inc. Filed by: Raben David

Tue, 26 May 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260526/26549732.html

Form 8-K Bicara Therapeutics Inc. For: May 21

Thu, 21 May 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260521/26536668.html